Bullous Pemphigoid Market to Witness Growth by 2032, Estimates DelveInsight | Companies- AstraZeneca, Kyowa Kirin, Regeneron, Sanofi, Argenx, Innate Pharma, ARTham Therapeutics, Kaken Pharmaceutical

DelveInsight's "Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Bullous Pemphigoid, historical and forecasted epidemiology as well as the Bullous Pemphigoid market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Bullous Pemphigoid market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Bullous Pemphigoid market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Bullous Pemphigoid treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Bullous Pemphigoid market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Bullous Pemphigoid: An Overview
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder, representing 80% of subepidermal immunobullous cases. Bullous pemphigoid most commonly affects elderly patients between the ages of 60 to 80 years. While the clinical presentation of bullous pemphigoid is broad, the immunobullous skin disorder characteristically presents with tense bullae and intense generalized pruritus. In atypical cases, bullous lesions may be absent, and these cases require a high degree of clinical suspicion. A biopsy for hematoxylin and eosin staining will show a subepidermal split with eosinophils, and direct immunofluorescence will highlight the autoantibodies against the basement membrane zone. ELISA testing is also useful in diagnosing bullous pemphigoid. Treatment depends on the severity of the disease; however, standard therapies involve topical or systemic immunosuppressive agents. The prognosis varies, and long-term monitoring is often required.

There are two main components to the pathophysiology of BP: immunologic and inflammatory. The immunologic elements comprise autoantibodies against two parts of the basal keratinocyte hemidesmosomal proteins, BP antigen 230 (BPAG1) and BP antigen 180 (BPAG2 or type XVII collagen). These antigens play an essential part in the adhesion complexes that promote epithelial-stromal adhesion. When autoantibodies bind to their target antigen, the inflammatory component follows, activating complement and mast cells. This causes neutrophils and eosinophils to release various inflammatory cells, resulting in the release of proteolytic enzymes that damage the dermal-epidermal junction.

In the prodromal phase, patients may experience moderate-to-severe pruritus alone or associated with urticarial or papular lesions. This later evolves to bullae in weeks to months, typically present in the axillae, on the flexor surface of the forearms, medial thighs, trunk, and abdomen. Approximately 20% of patients will have neither bullae nor erosions at the time of presentation. Constitutional symptoms are uncommon, except in widespread, severe disease. The bullous phase is characterised by the presence of vesicles and bullae on a background of normal or erythematous skin. The blisters are tense, up to 1 to 4 centimeters in diameter, and sometimes hemorrhagic. They typically contain a clear fluid and may persist for several days before leaving erosions and crusts. Unlike pemphigus vulgaris, the Nikolsky sign is negative in typical cases of bullous pemphigoid.

Childhood cases are rare. However, there have been cases of infantile bullous pemphigoid, which presents with an acral distribution in the first year of life. These cases need to be distinguished from other disorders due to their rarity. Therefore, direct immunofluorescence may be necessary. In some childhood cases, IgA antibodies against the NC16A domain of BP180 have been noted. It is also reported that the infancy subtype is not related to a maternofetal transfer of autoantibodies.

Researchers debate whether bullous pemphigoid is associated with internal malignancies. However, most believe this association is due to the older age of the patient. A recent study found no increased risk for concurrent or subsequent malignancies in patients with bullous pemphigoid.


Learn more about Bullous Pemphigoid, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Bullous Pemphigoid Market

The Bullous Pemphigoid market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Bullous Pemphigoid market trends by analyzing the impact of current Bullous Pemphigoid therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Bullous Pemphigoid market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Bullous Pemphigoid market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Bullous Pemphigoid market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Bullous Pemphigoid Epidemiology

The Bullous Pemphigoid epidemiology section provides insights into the historical and current Bullous Pemphigoid patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Bullous Pemphigoid market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Bullous Pemphigoid Epidemiology at: https://www.delveinsight.com/report-store/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Bullous Pemphigoid Drugs Uptake

This section focuses on the uptake rate of the potential Bullous Pemphigoid drugs recently launched in the Bullous Pemphigoid market or expected to be launched in 2019-2032. The analysis covers the Bullous Pemphigoid market uptake by drugs, patient uptake by therapies, and sales of each drug.

Bullous Pemphigoid Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Bullous Pemphigoid market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Bullous Pemphigoid Pipeline Development Activities

The Bullous Pemphigoid report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Bullous Pemphigoid key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Bullous Pemphigoid pipeline development activities at: https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Bullous Pemphigoid Therapeutics Assessment

Major key companies such as AstraZeneca, Kyowa Kirin, Regeneron, Sanofi, Argenx, Innate Pharma, ARTham Therapeutics, Kaken Pharmaceutical, and others are working proactively in the Bullous Pemphigoid Therapeutics market to develop novel therapies which will drive the Bullous Pemphigoid treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Bullous Pemphigoid Report Key Insights

1. Bullous Pemphigoid Patient Population
2. Bullous Pemphigoid Market Size and Trends
3. Key Cross Competition in the Bullous Pemphigoid Market
4. Bullous Pemphigoid Market Dynamics (Key Drivers and Barriers)
5. Bullous Pemphigoid Market Opportunities
6. Bullous Pemphigoid Therapeutic Approaches
7. Bullous Pemphigoid Pipeline Analysis
8. Bullous Pemphigoid Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Bullous Pemphigoid Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Bullous Pemphigoid Competitive Intelligence Analysis
4. Bullous Pemphigoid Market Overview at a Glance
5. Bullous Pemphigoid Disease Background and Overview
6. Bullous Pemphigoid Patient Journey
7. Bullous Pemphigoid Epidemiology and Patient Population
8. Bullous Pemphigoid Treatment Algorithm, Current Treatment, and Medical Practices
9. Bullous Pemphigoid Unmet Needs
10. Key Endpoints of Bullous Pemphigoid Treatment
11. Bullous Pemphigoid Marketed Products
12. Bullous Pemphigoid Emerging Therapies
13. Bullous Pemphigoid Seven Major Market Analysis
14. Attribute Analysis
15. Bullous Pemphigoid Market Outlook (7 major markets)
16. Bullous Pemphigoid Access and Reimbursement Overview
17. KOL Views on the Bullous Pemphigoid Market
18. Bullous Pemphigoid Market Drivers
19. Bullous Pemphigoid Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Bullous Pemphigoid Market report here: https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.